Show simple item record

dc.contributor.authorMcMillan, A. K.
dc.contributor.authorPhillips E H
dc.contributor.authorKirkwood, A. A.
dc.contributor.authorBarrans, S.
dc.contributor.authorBurton, C.
dc.contributor.authorRule, S.
dc.contributor.authorPatmore, R.
dc.contributor.authorPettengell, R.
dc.contributor.authorArdeshna, K. M.
dc.contributor.authorLawrie, A.
dc.contributor.authorMontoto, S.
dc.contributor.authorPaneesha, S.
dc.contributor.authorClifton-Hadley, L.
dc.contributor.authorLinch, D. C.
dc.date.accessioned2020-06-16T11:03:21Z
dc.date.available2020-06-16T11:03:21Z
dc.date.issued2020en
dc.identifier.citationA. K. McMillan, E. H. Phillips, A. A. Kirkwood et al. Favourable Outcomes for High-Risk Diffuse Large B-Cell Lymphoma (IPI 3-5) Treated with Front-Line R-CODOX-M/R-IVAC Chemotherapy: Results of a Phase 2 UK NCRI Trial. Ann Oncol. 2020.en
dc.identifier.pmid32464282en
dc.identifier.doi10.1016/j.annonc.2020.05.016en
dc.identifier.urihttp://hdl.handle.net/10541/623057
dc.description.abstractBACKGROUND: Outcomes for patients with high-risk diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy are suboptimal but, to date, no alternative regimen has been shown to improve survival rates. This phase 2 trial aimed to assess the efficacy of a Burkitt-like approach for high-risk DLBCL using the dose-intense R-CODOX-M/R-IVAC regimen. PATIENTS AND METHODS: Eligible pts were aged 18-65 years with stage II-IV untreated DLBCL and an International Prognostic Index (IPI) score of 3-5. Patients received alternating cycles of CODOX-M and IVAC (cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate [CODOX-M] alternating with ifosfamide, etoposide and high-dose cytarabine [IVAC]) chemotherapy plus 8 doses of rituximab. Response was assessed by CT after completing all 4 cycles of chemotherapy. The primary endpoint was 2-year progression-free survival (PFS). RESULTS: 111 eligible patients were registered; median age was 50 years, IPI score was 3 (60.4%) or 4-5 (39.6%), 54% had a performance status /=2 and 9% had central nervous system involvement. 85 patients (76.6%) completed all 4 cycles of chemotherapy. There were 5 treatment-related deaths (4.3%)en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2020.05.016en
dc.titleFavourable outcomes for high-risk diffuse large b-cell lymphoma (IPI 3-5) treated with front-line r-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI Trialen
dc.typeArticleen
dc.contributor.departmentHaematology, Nottingham University Hospitals NHS Trust, Nottinghamen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-06-16T14:04:29Z


Files in this item

Thumbnail
Name:
32464282.pdf
Size:
1.103Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record